Artikel

IGFBP-7 in CANVAS study

Insulin-like Growth Factor Binding Protein-7 in the Canagliflozin Cardiovascular Assessment Study

In this second video, Dr James Januzzi MD., Hutter Family Professor of Medicine at Harvard Medical School and Cardiologist at the Massachusetts General Hospital, shares his valuable insights into another biomarker measured and analyzed from the CANVAS study, the insulin-like growth factor-binding protein-7 (IGFBP-7).

A novel aspect of his research is the evaluation of blood IGFBP-7 measurements over a period of time - at baseline, 1 year and 6 year - in relation to risk of cardiovascular events and to chronic kidney complications - specifically diabetic kidney disease (DKD).

A major finding was that a rising value of IGFBP-7 was strongly associated with a worse prognosis and increased the risk of cardiovascular events. A rising value was more significant than an elevated level at baseline. IGFBP-7 was also strongly associated with the development and progression of chronic kidney disease in patients with diabetes.

A second major finding suggests that treatment of T2DM patients with the novel Sodium-glucose Cotransporter-2 inhibitors (SGLT2 inhibitors) - specifically Canagliflozin - could reduce the future risk of developing DKD and heart failure.

Plasma IGFBP-7 concentrations predicted cardiac events among T2DM patients and high cardiovascular risk. With validation from future research, these findings have the potential to predict the risk for DKD and the benefits of a therapy, such as SGLT-2 inhibitors, to not only prevent its onset, but to delay its progression.

Key facts
  • Discover the latest insights from Dr Januzzi as he talks about some very exciting data that could have strong implications for future clinical guidelines
  • His most recent research illustrates how biomarkers in addition to NT-proBNP can provide unique and powerful prognostic information.
  • Another unique finding highlights the importance of repeated IGFBP-7 measurements as rising concentrations provide significant implications and more information for the risk of development and progression of DKD.
  • Measuring and understanding elevated levels of biomarkers like IGFBP-7 can result in better decision making and lead to personalized prescribing of treatments like Canagliflozin that would maximize the benefit and quality of care for the patient.